The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences

BACKGROUND: In 2014 the European Medicines Agency included exon 2, 3 and 4 KRAS and NRAS testing for the selection of metastatic colorectal cancer (mCRC) patients eligible for the therapy with anti-EGFR monoclonal antibodies. The Italian Association of Medical Oncology (AIOM) and the Italian Society...

Descripción completa

Detalles Bibliográficos
Autores principales: Normanno, Nicola, Pinto, Carmine, Castiglione, Francesca, Fenizia, Francesca, Barberis, Massimo, Marchetti, Antonio, Fontanini, Gabriella, De Rosa, Gaetano, Taddei, Gian Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4557483/
https://www.ncbi.nlm.nih.gov/pubmed/26335936
http://dx.doi.org/10.1186/s12967-015-0655-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4557483/
https://www.ncbi.nlm.nih.gov/pubmed/26335936
http://dx.doi.org/10.1186/s12967-015-0655-1

Ejemplares similares